Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
HLA-B51/B5 and the risk of Behçets disease: A systematic review and meta-analysis of case-control genetic association studies
Arthritis Care and Research , 10/02/09
de Menthon M et al. – The strength of the association between BD and HLA-B51/B5, and its consistency across populations of various ethnicities, lends further support to this allele being a primary and causal risk determinant for BD. Variations according to sex support an interaction of this allele with BD characteristics.
Methods- Relevant studies identified using PubMed Medline database and manual searches of the literature
- Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using the random-effects model
- Subgroup meta-analyses and meta-regression analyses undertaken to investigate effects of selected study-level parameters on pooled OR
- Heterogeneity assessed using I2 statistic
- Pooled results were used to calculate population-attributable risks (PAR) for BD in relationship to HLA-B51/B5
- 4,800 patients with BD from 78 independent studies (published 1975-2007)
- 16,289 controls from 78 independent studies (published 1975-2007) selected
- Pooled OR of HLA-B51/B5 allele carriers to develop BD compared with noncarriers was 5.78 (95% CI 5.00-6.67), with moderate between-study heterogeneity (I2 = 61%)
- Subgroup analyses stratifying studies by geographic locations (Eastern Asia, Middle East/North Africa, Southern Europe, Northern/Eastern Europe) yielded consistent OR ranges (5.31-7.20), with I2 ranges of 52-70%
- Univariate random-effects meta-regression indicated percentage of male BD cases as source of heterogeneity
- PAR within the various geographic areas estimated at 32-52%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/13/09
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09
Today in Vasculitic Syndromes...keeping you current
Receive free subspecialty "5-minute updates" via email
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçets disease refractory to standard immunosuppressive drugs
Rheumatology International, 10/30/09
Vasculitis in Children and Adolescents: Clinical Presentation, Etiopathogenesis, and Treatment
Pediatric Drugs, 11/11/09
Management of acute coronary syndrome in a case of Behcets disease
Blood Coagulation & Fibrinolysis, 11/03/09
Sponsor
Article Search
Sponsor


See Latest Articles


